New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
09:04 EDTABBV, ENTA, DLLR, TNP, TSN, CMG, AMZN, SLCA, LYB, CTXS, MAT, ZNGA, GOOG, IMGN, CYTR, JDSU, MA, WMT, NOVOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Google (GOOG), up 4%... Chipotle (CMG), up 11.8%... JDSU (JDSU), up 6%... Tyson Foods (TSN), up 2.6%... ImmunoGen (IMGN), up 7%... LyondellBasell (LYB), up 2.4%... National-Oilwell Varco (NOV), up 1.8%. ALSO HIGHER: Zynga (ZNGA), up 18% after pre-announcing results, announcing job cuts and agreeing to buy privately-held NaturalMotion for about $527M... Citrix (CTXS), up 2% after upgrades at Nomura and JPMorgan... Enanta Pharmaceuticals (ENTA), up 15% after reporting on studies being conducted by AbbVie (ABBV) for the treatment of genotype 1 hepatitis C virus. DOWN AFTER EARNINGS: Amazon (AMZN), down 8%... Mastercard (MA), down 5.6%... Mattel (MAT), down 10%... U.S. Silica (SLCA), down 14%... DFC Global (DLLR), down 22.8%. ALSO LOWER: Wal-Mart (WMT), down xx% after warning now sees Q4 EPS at or slightly below low end of prior view.
News For GOOG;AMZN;WMT;ZNGA;CMG;MA;MAT;TSN;JDSU;CTXS;TNP;CYTR;LYB;NOV;IMGN;SLCA;DLLR;ENTA;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 9, 2014
06:29 EDTAMZNAmazon warns of moving more drone research abroad, WSJ reports
Subscribe for More Information
06:23 EDTAMZNAmazon.com testing faster deliveries through bikes, drones, WSJ reports
Subscribe for More Information
06:16 EDTAMZNAmazon unveils 'Make an Offer' for customers to negotiate lower prices
Amazon.com has announced the "Make an Offer" experience that allows customers to negotiate even lower prices on thousands of items. Expanding on Amazonís traditional fixed price model, the new pricing feature allows customers to offer to buy items at even lower prices. If agreed upon, customers can then purchase the items at a savings from the listed price. To start, more than 150,000 items from sellers on Amazon are enabled with the "Make an Offer" experience across Sports and Entertainment Collectibles, Collectible Coins and Fine Art. The new feature will expand to hundreds of thousands of items from sellers in 2015. The "Make an Offer" feature is not an auction format. All negotiations are 1:1 and private between individual customers and sellers. A seller is able to accept a customerís offer at any time. The intention is to lower prices, and a customer negotiating with a seller will never pay more than the listed price.
06:14 EDTGOOGGoogle launches Street View in Dubai
Subscribe for More Information
06:00 EDTGOOGSalesforce.com names YouTube CEO Susan Wojcicki to board
Subscribe for More Information
05:34 EDTAMZNChannelAdvisor says Amazon November SSS up 35.7%, eBay up 9.8%
Subscribe for More Information
December 8, 2014
16:24 EDTWMTOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the dayís activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
16:00 EDTAMZNOptions Update; December 8, 2014
Subscribe for More Information
14:50 EDTMAVisa price target raised to $295 from $260 at Argus
Argus raised its FY15 and FY16 adjusted EPS estimates for Visa (V) and correspondingly increased its price target on the stock to $295 from $260. The firm, which keeps a Buy rating on Visa, expects rising transaction volume to lead to higher consensus earnings estimates and believes the stock should trade at a higher multiple than peer MasterCard (MA), given its faster EPS growth rate and more consistent earnings performance.
12:40 EDTWMTOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTWMTLiquidity Services plunges after Wal-Mart seeks to end supply deal
Shares of Liquidity Services (LQDT) are tumbling after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with merchandise. Liquidity Services operates an auction marketplace that features surplus and salvaged items. WHAT'S NEW: Liquidity Services reported after Friday's market close in a regulatory filing that Wal-Mart had decided to stop supplying products to Liquidity Services.The auction company noted that it had previously had the right to purchase certain consumer items that have been removed from Wal-Mart's shelves. However, Wal-Mart, on December 1, reported to the company that it would terminate the deal, effective today. Wal-Mart is alleging that Liquidity Services violated certain requirements of the agreement between the companies, Liquidity Services stated. However, the auction company disputed Wal-Mart's assertions and said it was "evaluating all its options" before determining how to proceed. Liquidity Services indicated that it still expects to meet its guidance for its December quarter results. ANALYST REACTION: In a note to investors today, Colin Sebastian, an analyst at research firm Robert W. Baird, predicted that the loss of the contract would have a significant impact on Liquidity Services' results starting in 2015. However, he believes that the extent of the impact on the company's earnings before interest taxes depreciation and amortization will depend on its ability to manage its expenses. The analyst cut his price target on the name to $9 from $12 and kept a Neutral rating on the shares. Meanwhile, Janney Capital analyst Shawn Milne wrote that Liquidity Services had previously disclosed that Wal-Mart accounted for 11% of its gross merchandise volume in fiscal 2014. Milne predicted that the termination of the deal would reduce Liquidity Services' annual EBITDA by less than $10M. He also kept a Neutral rating on the stock. PRICE ACTION: In early trading, Liquidity Services sank 25% to $7.70.
10:03 EDTWMTLiquidity Services price target lowered to $9 from $12 at RW Baird
Subscribe for More Information
09:20 EDTWMTLiquidity Services estimate cuts possible on Wal-Mart fight, says Janney Capital
After Liquidity Services (LQDT) disclosed that Wal-Mart (WMT) terminated its return agreement and that the two are now in dispute over the deal, Janney Capital noted Liquidity 's recent 10K filing indicated that Wal-Mart accounted for 11% of FY14 gross merchandise volume, including Commercial Capital assets. Janney estimates the full year EBITDA impact from the contract to be somewhere below $10M, but said there is a potential for further estimate cuts given the dispute. The firm maintains its Neutral rating on Liquidity Services shares.
09:13 EDTWMTLiquidity Services reports Walmart terminates return agreement
Liquidity Services (LQDT) had previously acquired from ILJ Enterprises its business of purchasing closeouts, excess merchandise and customer returns for resale to retailers, wholesalers, and other third parties and consumers. In connection with the acquisition, the company, through one of its subsidiaries, assumed ILJís rights and obligations with Wal-Mart Stores (WMT). Under the Wal-Mart agreement, Liquidity Services has the exclusive right to purchase certain consumer products from Wal-Mart that have been removed from the sales stream of Wal-Martís retail operations. On December 1, Wal-Mart provided Liquidity Services written notice terminating the Wal-Mart Agreement, effective December 8. The termination notice alleges that the company failed to comply with certain provisions under the Wal-Mart agreement with respect to service level requirements and restrictions on the disposition of merchandise, Liquidity disclosed in a regulatory filing late Friday. The company disputes these allegations and is contesting the termination of the agreement with Wal-Mart. The company had been in negotiations with Wal-Mart to address Wal-Martís failure to honor the companyís exclusive right to purchase selected merchandise from Wal-Mart but was unable to reach a satisfactory resolution. The company is currently evaluating all of its options, reserves all rights with respect to this matter and will continue to seek appropriate relief from Wal-Mart for its failure to honor the companyís exclusive rights to purchase selected merchandise and any related actual damages the company has incurred. The company does not believe that the purported termination of the Wal-Mart Agreement will result in the company being unable to meet its financial guidance for its first fiscal quarter ending December 31, 2014, Liquidity Services stated.
09:04 EDTMAMasterCard, Dynamics announce joint commercial initiative
In conjunction with the Series C funding announcement issued earlier, MasterCard and Dynamics Inc. also announced a joint commercial initiative to drive innovation in the interactive payment card market. The collaboration enables MasterCard to offer exclusive Dynamics products to its issuers globally, providing consumers with added choice, flexibility and security at the point of sale.
08:50 EDTAMZNAmazon increasing robot fulfilment use faster than expected, says Janney Capital
Subscribe for More Information
06:47 EDTCMGChipotle coverage resumed with a Buy at Goldman
Subscribe for More Information
06:30 EDTAMZNAmazon's German workers strike again, WSJ reports
Subscribe for More Information
December 7, 2014
13:47 EDTGOOGGoogle could reach $634 in a year, Barron's says
Google shares look attractive at current levels and shares could reach $634.00 in a year, driven by stabilizing ad pricing, Barron's contends in a feature article. Reference Link
12:53 EDTIMGNImmunoGen announces 'encouraging' IMGN529 clinical data
ImmunoGen announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology annual meeting. These include objective responses at doses that were generally well tolerated. ImmunoGenís IMGN529 is a potential new treatment for DLBCL and other non-Hodgkin lymphoma, NHL, subtypes. An ADC, it comprises an antibody that targets CD37, found on B-cell malignancies, with the potent cancer cell-killing agent, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity. IMGN529 is currently in the dose-finding portion of a Phase I clinical trial, which assesses increasing doses of this experimental therapy in new groups of patients with relapsed/refractory NHL. Findings with the first doses evaluated were reported previously.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use